Together, these results suggest that initial treatment with a combination of ALK-TKIs and afatinib may prevent the development of intrinsic ALK-TKI resistance and the emergence of DT cells with MET in ALK-rearranged NSCLC, leading to the potential eradication of these tumors. Here, MET is linked to non-small cell lung carcinoma.